February 20, 2025

Dear Honorable Legislators,

On behalf of the undersigned patient and provider organizations, we encourage you to support HB 6771 – AN ACT REQUIRING HEALTH INSURANCE COVERAGE FOR BIOMARKER TESTING, as proposed to be amended, to expand access to comprehensive biomarker testing in Connecticut. **Biomarker testing and precision treatments based on patients' biomarkers can lead to better health outcomes and improved quality of life for patients facing cancer and other serious conditions across the state.**

Biomarker testing is a component of precision medicine that looks for biomarkers – molecules like proteins and genetic alterations that can provide information about a patient's cancer or other condition. The results can help doctors choose the most effective treatment for an individual patient. Biomarker testing is essential to high-quality, personalized care for many conditions and can be a real gamechanger for many patients, but unfortunately, not everyone who can benefit from biomarker testing is getting it.

Insurance coverage of biomarker testing has not kept pace with the speed of medical innovation, contributing to significant disparities in who is benefiting from biomarker testing and biomarker-informed treatment. Thankfully, this proposed amendment to HB 6771 will increase access to this important testing by ensuring state-regulated private insurance plans will cover this critically important testing when it's supported by medical and scientific evidence.

While most current applications are in cancer, biomarker testing is becoming increasingly important to the treatment of other disease areas including arthritis, other autoimmune conditions, organ and tissue transplant, rare diseases, and preeclampsia. There is biomarker research happening in many other areas including Alzheimer's, other neurological conditions, cardiology and more. Current non-oncology biomarker testing applications could be used to address common comorbidities in cancer patients and survivors and as personalized medicine continues to evolve, non-oncology biomarker testing applications will likely have an increasing role in guiding treatment for patients.

There are significant disparities in health outcomes for Connecticut patients by race, income, and insurance type. And without action to address barriers to care, breakthroughs in personalized treatments could increase these disparities in health outcomes. Already, 20 states, including New York, Texas, Kentucky, and Rhode Island have passed similar laws to increase access to comprehensive biomarker testing—**and it's time for Connecticut to do the same.** Last year, the Connecticut legislature did take important action to ensure such access for Medicaid enrollees in our state.

Expanding access to biomarker testing through HB 6771, as proposed to be amended, will help more people in Connecticut get the right treatment at the right time and avoid therapies that are unnecessary or ineffective for their condition. Thank you for your attention to this critical issue, and we welcome the opportunity to speak with you further. For more information, please contact Bryte Johnson, Connecticut government relations director for the American Cancer Society Cancer Action Network at <u>bryte.johnson@cancer.org</u>.

Sincerely,

AiArthritis: International Foundation for Autoimmune & Autoinflammatory Arthritis **ALS Association** ALS United Connecticut Alzheimer's Association American Academy of Pediatrics – Hezekiah Beardsley Connecticut Chapter American Association of Clinical Urologists American Cancer Society Cancer Action Network American Kidney Fund American Lung Association Arthritis Foundation BIOCT **Biomarker Collaborative** Cancer*Care* **Cancer Support Community CBIA Bioscience Growth Council CLL Society** Coalition of State Rheumatology Orgs **Colon Cancer Coalition** Community Health Center Association of CT **CT** Academy of Family Practice Physicians **Connecticut Oncology Association** Crohn's & Colitis Foundation Debbie's Dream Foundation: Curing Stomach Cancer End Preeclampsia Exon 20 Group

Fight Colorectal Cancer Global Colon Cancer Association Global Liver Institute GO2 for Lung Cancer Honor the Gift ICAN, International Cancer Advocacy Network The Jackson Laboratory **KRAS Kickers** Lung Cancer Research Foundation LUNGevity Foundation Lupus and Allied Diseases Association, Inc. **MET Crusaders** Michael J. Fox Foundation National Oncology State Network National Ovarian Cancer Coalition NMDP (formerly National Marrow Donor Program) Oncology Nursing Society One Cancer Place Patient Empowerment Network Patients Rising PD-L1 Amplifieds Sharsheret Stupid Cancer, Inc. Susan G. Komen Connecticut **Triage Cancer** VHL Alliance ZERO Prostate Cancer

















	American
	Academy of
	Pediatrics
	HEZEKIAH BEARDSLEY

HEZEKIAH BEARDSLEY CONNECTICUT CHAPTER 750 Main Street, Suite 100, Hartford CT 06103, Tel. (860) 525-9738, Fax (609) 394-7712






















CONNECTICUT ONCOLOGY ASSOCIATION







nternational

cancer advocacy



The Jackson

Laboratory

Leading the search

orrow's cures

for ton



LUNG CANCER RESEARCH FOUNDATION.























KRAS

KICKERS



